结构GLA蛋白变化对法布里病患者外周GLA活性和底物积累的影响

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Jorge Diogo Da Silva, Isaura Ribeiro, Carla Caseiro, Eugénia Pinto, Sónia Rocha, Helena Ribeiro, Célia Ferreira, Elisabete Silva, Francisco Laranjeira, Nataliya Tkachenko, Lúcia Lacerda, Dulce Quelhas
{"title":"结构GLA蛋白变化对法布里病患者外周GLA活性和底物积累的影响","authors":"Jorge Diogo Da Silva,&nbsp;Isaura Ribeiro,&nbsp;Carla Caseiro,&nbsp;Eugénia Pinto,&nbsp;Sónia Rocha,&nbsp;Helena Ribeiro,&nbsp;Célia Ferreira,&nbsp;Elisabete Silva,&nbsp;Francisco Laranjeira,&nbsp;Nataliya Tkachenko,&nbsp;Lúcia Lacerda,&nbsp;Dulce Quelhas","doi":"10.2174/1871530323666230914114414","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to decreased/absent α-galactosidase activity. In clinical practice, enzyme activity and substrate/byproduct accumulation play a role in diagnosis and disease-monitoring biomarkers. However, interpreting biomarker levels is not straightforward and can change according to the underlying GLA protein abnormality.</p><p><strong>Objective: </strong>Our goals were to understand how disrupting specific protein regions changes biomarker behaviour and to establish specific patterns for individual variants.</p><p><strong>Methodology: </strong>We analysed data from the Biochemical Genetics Laboratory regarding GLA variants, GLA enzyme activity (in dried blood spots, plasma or white blood cells), plasma LysoGb3 accumulation, and urinary Gb3 excretion. We assessed correlations, trends, and potential predictor models of biomarker behaviour.</p><p><strong>Results: </strong>We assessed 169 hemizygous male and 255 heterozygous female patients. For both groups, substrate accumulation correlates inversely with GLA activity. Variants affecting residues buried within the protein core or the active site were associated with more severe biomarker changes, while those affecting residues that establish disulfide bonds or are glycosylated were similar to other variants. For each non-truncating variant, we also established specific profiles of biomarker behaviour. Finally, we also designed predictor models of biomarker behaviour based on structural variant information. This study provides the groundwork for the impact of GLA protein variation on GLA activity and substrate accumulation.</p><p><strong>Conclusion: </strong>This knowledge is of extreme relevance for diagnostic labs and clinicians, as some genetic variants are challenging to interpret regarding pathogenicity. Assessing whether biomarker changes are in the expected range for a specific variant may help diagnostic evaluation. This study also contributes to recognising non-disease-causing variants, considering their overall biochemical impact, and providing a comparative reference for biomarker discovery studies. In the future, the correlation of these findings with disease severity may be of great relevance for diagnosis and monitoring progression.</p>","PeriodicalId":11614,"journal":{"name":"Endocrine, metabolic & immune disorders drug targets","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2023-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of Structural GLA Protein Changes on Peripheral GLA Activity and Substrate Accumulation in Fabry Disease Patients.\",\"authors\":\"Jorge Diogo Da Silva,&nbsp;Isaura Ribeiro,&nbsp;Carla Caseiro,&nbsp;Eugénia Pinto,&nbsp;Sónia Rocha,&nbsp;Helena Ribeiro,&nbsp;Célia Ferreira,&nbsp;Elisabete Silva,&nbsp;Francisco Laranjeira,&nbsp;Nataliya Tkachenko,&nbsp;Lúcia Lacerda,&nbsp;Dulce Quelhas\",\"doi\":\"10.2174/1871530323666230914114414\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to decreased/absent α-galactosidase activity. In clinical practice, enzyme activity and substrate/byproduct accumulation play a role in diagnosis and disease-monitoring biomarkers. However, interpreting biomarker levels is not straightforward and can change according to the underlying GLA protein abnormality.</p><p><strong>Objective: </strong>Our goals were to understand how disrupting specific protein regions changes biomarker behaviour and to establish specific patterns for individual variants.</p><p><strong>Methodology: </strong>We analysed data from the Biochemical Genetics Laboratory regarding GLA variants, GLA enzyme activity (in dried blood spots, plasma or white blood cells), plasma LysoGb3 accumulation, and urinary Gb3 excretion. We assessed correlations, trends, and potential predictor models of biomarker behaviour.</p><p><strong>Results: </strong>We assessed 169 hemizygous male and 255 heterozygous female patients. For both groups, substrate accumulation correlates inversely with GLA activity. Variants affecting residues buried within the protein core or the active site were associated with more severe biomarker changes, while those affecting residues that establish disulfide bonds or are glycosylated were similar to other variants. For each non-truncating variant, we also established specific profiles of biomarker behaviour. Finally, we also designed predictor models of biomarker behaviour based on structural variant information. This study provides the groundwork for the impact of GLA protein variation on GLA activity and substrate accumulation.</p><p><strong>Conclusion: </strong>This knowledge is of extreme relevance for diagnostic labs and clinicians, as some genetic variants are challenging to interpret regarding pathogenicity. Assessing whether biomarker changes are in the expected range for a specific variant may help diagnostic evaluation. This study also contributes to recognising non-disease-causing variants, considering their overall biochemical impact, and providing a comparative reference for biomarker discovery studies. In the future, the correlation of these findings with disease severity may be of great relevance for diagnosis and monitoring progression.</p>\",\"PeriodicalId\":11614,\"journal\":{\"name\":\"Endocrine, metabolic & immune disorders drug targets\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2023-09-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Endocrine, metabolic & immune disorders drug targets\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1871530323666230914114414\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine, metabolic & immune disorders drug targets","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1871530323666230914114414","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

简介:法布里病是一种由GLA基因致病性变异引起的x连锁溶酶体贮积症,导致α-半乳糖苷酶活性降低或缺失。在临床实践中,酶活性和底物/副产物积累在诊断和疾病监测的生物标志物中起着重要作用。然而,解释生物标志物水平并不是直截了当的,它可以根据潜在的GLA蛋白异常而改变。目的:我们的目标是了解破坏特定蛋白质区域如何改变生物标志物的行为,并建立个体变异的特定模式。方法:我们分析了生化遗传学实验室关于GLA变异、GLA酶活性(在干血斑、血浆或白细胞中)、血浆溶酶Gb3积累和尿Gb3排泄的数据。我们评估了生物标志物行为的相关性、趋势和潜在的预测模型。结果:我们评估了169例半合子男性和255例杂合子女性患者。在两组中,底物积累与GLA活性呈负相关。影响埋在蛋白质核心或活性位点内残基的变异与更严重的生物标志物变化相关,而影响建立二硫键或糖基化的残基的变异与其他变异相似。对于每个非截断变体,我们还建立了生物标志物行为的特定概况。最后,我们还设计了基于结构变异信息的生物标志物行为预测模型。本研究为GLA蛋白变化对GLA活性和底物积累的影响奠定了基础。结论:这些知识对于诊断实验室和临床医生来说是非常重要的,因为一些遗传变异在致病性方面是具有挑战性的。评估生物标志物变化是否在特定变异的预期范围内可能有助于诊断评估。该研究还有助于识别非致病变异,考虑其整体生化影响,并为生物标志物发现研究提供比较参考。在未来,这些发现与疾病严重程度的相关性可能对诊断和监测进展具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Impact of Structural GLA Protein Changes on Peripheral GLA Activity and Substrate Accumulation in Fabry Disease Patients.

Introduction: Fabry disease is an X-linked lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to decreased/absent α-galactosidase activity. In clinical practice, enzyme activity and substrate/byproduct accumulation play a role in diagnosis and disease-monitoring biomarkers. However, interpreting biomarker levels is not straightforward and can change according to the underlying GLA protein abnormality.

Objective: Our goals were to understand how disrupting specific protein regions changes biomarker behaviour and to establish specific patterns for individual variants.

Methodology: We analysed data from the Biochemical Genetics Laboratory regarding GLA variants, GLA enzyme activity (in dried blood spots, plasma or white blood cells), plasma LysoGb3 accumulation, and urinary Gb3 excretion. We assessed correlations, trends, and potential predictor models of biomarker behaviour.

Results: We assessed 169 hemizygous male and 255 heterozygous female patients. For both groups, substrate accumulation correlates inversely with GLA activity. Variants affecting residues buried within the protein core or the active site were associated with more severe biomarker changes, while those affecting residues that establish disulfide bonds or are glycosylated were similar to other variants. For each non-truncating variant, we also established specific profiles of biomarker behaviour. Finally, we also designed predictor models of biomarker behaviour based on structural variant information. This study provides the groundwork for the impact of GLA protein variation on GLA activity and substrate accumulation.

Conclusion: This knowledge is of extreme relevance for diagnostic labs and clinicians, as some genetic variants are challenging to interpret regarding pathogenicity. Assessing whether biomarker changes are in the expected range for a specific variant may help diagnostic evaluation. This study also contributes to recognising non-disease-causing variants, considering their overall biochemical impact, and providing a comparative reference for biomarker discovery studies. In the future, the correlation of these findings with disease severity may be of great relevance for diagnosis and monitoring progression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Endocrine, metabolic & immune disorders drug targets
Endocrine, metabolic & immune disorders drug targets ENDOCRINOLOGY & METABOLISMIMMUNOLOGY-IMMUNOLOGY
CiteScore
4.60
自引率
5.30%
发文量
217
期刊介绍: Aims & Scope This journal is devoted to timely reviews and original articles of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Moreover, the topics related to effects of food components and/or nutraceuticals on the endocrine-metabolic-immune axis and on microbioma composition are welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信